FDA, Advocacy Group Clash Over Hydroxychloroquine

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

Read the full article here

Related Articles